14.02.2013 • NewsHaloPolymerchemical industrychemicals

HaloPolymer Completes Reorganization of R-14 Production Capacity

Upon rehabilitation completion in February 2013, HaloPolymer saw the starting of R-14 manufacturing, which allowed practical doubling of volume of the finished product output, bringing it up to 20 tons per month.

The global market volume of R-14 is estimated to be at about 1.5 thousand tons per year. At present, the HaloPolymer share in the world's market is 8%.

"R-14 is in high demand traditionally, and according to our forecast it will grow in the near future", the CEO of HaloPolymer, Maxim Doroshkevich said. "In Russia, our holding is the sole manufacturer of this product. We supply R-14 to the Russian market and to the leaders of the global market of industrial gases in Germany, France and the USA."

R-14 is used primarily for plasma etching of dielectrics when manufacturing integrated circuits, and as an inert gas during obtaining rare earth metals. It is also used as an additive to the sulfur hexafluoride in the high-voltage equipment that is used at low temperatures to reduce the dew point. Moreover, R-14 is designed to prepare breathing mixtures for deep-sea diving, as a refrigerant, fire retardant, stabilizer of ozone decomposition, diluter for performing chemical reactions, reactant for producing fluorine-organic products.

 

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.